Postbiotic preparation for pelvic floor muscle rehabilitation and preparation method and application thereof
A postbiotic formulation from Lactobacillus plantarum Nice-02 addresses the ineffectiveness and side effects of existing pelvic floor muscle treatments by promoting smooth muscle contraction and repairing damage, offering a quick and effective solution for conditions like stress urinary incontinence.
Patent Information
- Application Number
- JP2024003821
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-06
- Filing Date
- 2024-01-15
- Publication Date
- 2024-11-18
- Estimated Expiration
- 2044-01-15
AI Technical Summary
Current treatments for pelvic floor muscle dysfunction, such as urinary incontinence, are ineffective, expensive, and associated with significant side effects, and there is a lack of effective medical methods that women are willing to use due to embarrassment and fear of medical examinations.
A postbiotic formulation produced from Lactobacillus plantarum Nice-02, including its fermentation metabolites, is developed through a specific fermentation process to promote smooth muscle contraction and repair pelvic floor muscle damage.
The postbiotic formulation effectively promotes smooth muscle contraction and repairs pelvic floor muscle damage, providing a quick and effective solution to conditions like stress urinary incontinence with reduced side effects and improved patient compliance.
Smart Images

Figure 2024161318000001 
Figure 2024161318000002
Abstract
Description
[Technical field]
[0001] The present invention relates to the technical fields of microbiology and biomedicine, and in particular to a postbiotic preparation for repairing pelvic floor muscles and its preparation method and application. [Background technology]
[0002] The disclosure of the information in the Background section is solely for the purpose of enhancing understanding of the overall background of the present invention, and is not necessarily to be construed as an admission or in any way suggesting that the information constitutes prior art known to those skilled in the art.
[0003] The female pelvic floor muscles (PFMs) span the pelvic outlet, support the pelvic and abdominal viscera, aid in urinary and fecal control, and achieve sexual function. In humans, the PFMs include the levator ani complex, which is composed of the medial (puborectalis) and lateral (pubococcygeus) portions of the pubococcygeus and posterior tail muscles. PFM dysfunction is one of the major causes of the progression of pelvic floor disorders, including pelvic organ prolapse, urinary incontinence, and fecal incontinence. Factors such as aging, pregnancy, and vaginal delivery can cause a decrease in pelvic floor muscle contractility or structural damage, and the pelvic floor support structures cannot counteract intraperitoneal pressure, ultimately leading to stress urinary incontinence and pelvic organ prolapse. Stress urinary incontinence (SUI), likened to an invisible "social cancer," is a common condition that affects many middle-aged and elderly women, and is defined as the involuntary leakage of urine when abdominal pressure increases due to coughing, laughing, etc. The onset of this condition is very private, and patients are embarrassed to talk about it or have no way to seek help, which has a significant negative impact on patients' lives, relationships, and psychological health.
[0004] Currently, the treatment modalities for pelvic floor dysfunction disorders include conservative, pharmacological and surgical treatments, including the use of mats, catheters or urinals, dieting, smoking cessation, behavioral treatments (i.e. bladder training, fluid / dietary changes, reduced caffeine intake), physical therapy and electrophysiological stimulation of the pelvic floor. However, due to lack of motivation, lack of continuity and inconsistency in implementation, conservative treatments are generally ineffective. Anticholinergics and / or beta-3 receptor agonists are most commonly used for mixed urinary incontinence, but long-term use of these medications can have significant side effects. There are various surgical options, including urethral injection therapy, tension-free vaginal bands, pubovaginal or midurethral slings and Burch colposuspension. However, these options can only provide short-term relief, and in the long term, they often lead to complications such as bladder or vaginal perforation, voiding or storage dysfunction, chronic pelvic pain, urethral or vaginal erosion, or material infection.
[0005] At present, medically, there are no other methods to quickly and effectively improve female pelvic floor muscle problems other than the above three methods, but the above treatment methods are expensive and prone to postoperative pain, infection, inflammation and other unspoken problems. Many women are embarrassed to speak about their pelvic floor muscle problems and are afraid to go to a doctor by themselves, so using oral regulators to gradually improve the troubles of pelvic floor muscle problems is a good solution. According to the above analysis, the advantages of pelvic floor muscle repair by oral postbiotics are obviously greater than medical treatment. Summary of the Invention
[0006] Based on the above-mentioned shortcomings of the prior art, the present invention provides a postbiotics preparation for repairing pelvic floor muscles, and its manufacturing method and application. The postbiotics preparation prepared in the present invention has been verified by animal and human experiments to have the effect of promoting smooth muscle contraction and repairing pelvic floor muscle damage, thereby effectively solving the problems of large side effects, poor therapeutic effect, and poor patient compliance of conventional treatment methods. Based on the above-mentioned research results, the present invention has been completed.
[0007] To achieve the above technical objectives, the present invention relates to the following technical solutions:
[0008] In one aspect of the present invention, there is provided Lactobacillus plantarum Nice-02, which is deposited at the China Typical Culture Preservation Center (Address: Wuhan University, Luojiashan, Wuchang, Wuhan City, Hubei Province), the date of deposit is April 21, 2023, and the biological deposit number is CCTCC NO:M 2023571.
[0009] In a second aspect of the present invention, there is provided a microbial agent containing at least the above-mentioned Lactobacillus plantarum and / or a fermentation metabolite thereof.
[0010] Furthermore, the microbial agent includes inactivated Lactobacillus plantarum and its fermentation metabolites, including, but not limited to, extracellular polysaccharides, polypeptides, and amino acids, in which case the microbial agent is a postbiotic preparation.
[0011] Therefore, in a third aspect of the present invention, S1 A step of strain activation in which the Lactobacillus plantarum Nice-02 is streaked on an activation medium to obtain a pure strain; S2: Pick up the Lactobacillus plantarum Nice-02 single colony produced in step S1, place it in the first culture medium at 28-30°C, and culture it for 12-14 hours to obtain the first seed liquid. S3: A step of preparing a secondary seed liquid by inoculating the above-mentioned primary seed liquid into a second culture liquid at an inoculation amount of 0.1 to 5% (preferably 0.5%, v / v) and statically culturing the liquid at 30 to 40°C (preferably 37°C) for 10 to 12 hours to obtain a secondary seed liquid; S4: A step of preparing a third seed liquid by inoculating the above-cultured second seed liquid into a seed tank containing a third culture liquid under sterile conditions, culturing the second seed liquid at an inoculation amount of 0.5 to 5% (preferably 2%) at 20 to 50 rotations / min (preferably 30 rotations / min) under stirring at a temperature of 30 to 40°C (preferably 37°C), pH of 7.0, tank pressure of 0.03 to 0.06 MPa (preferably 0.05 MPa) for 10 to 12 hours to obtain a third seed liquid; S5: The tertiary seed liquid is inoculated into a fermentation tank containing a sterilized culture medium, and the inoculation amount is 0.5-5% (preferably 2%), and the Lactobacillus plantarum is cultured at 32°C and 40-50r / min (preferably 45r / min) for 5-6 hours for primary fermentation. S6 After 5-6 hours, the fermentation temperature is lowered to 30°C, the stirring speed is increased to 50-70r / min (preferably 60r / min), the tank pressure is maintained at 0.05MPa, and the pH is kept natural for 3-4 hours for the Lactobacillus plantarum secondary fermentation step; S7 After 8-10 hours, the stirring speed is not changed, the fermentation temperature is increased to 35°C, the tank pressure is maintained at 0.05MPa, and the pH is maintained at 6.5, and the Lactobacillus plantarum tertiary fermentation step is carried out for 2 hours. S8 After 10-12 hours, reduce the rotation speed of the agitator to 30-40r / min (preferably 40r / min), raise the fermentation temperature to 40°C, maintain the tank pressure at 0.05MPa, maintain the pH at 6.5, and ferment for 1-2 hours for the fourth fermentation step of Lactobacillus plantarum; S9 After 11 to 14 hours, the stirring speed is not changed, the temperature is raised to 45°C, 0.05 to 0.2% (preferably 0.1%) of sterilized lipoteichoic acid of the fermentation liquid volume is added to the fermentation tank, the temperature is lowered to 20°C, and the temperature is maintained for 30 minutes to perform Lactobacillus plantarum fifth fermentation.
[0012] In a fourth aspect, the present invention provides the application of the postbiotic formulation in the manufacture of a pelvic floor muscle repair product.
[0013] The pelvic floor muscle repair product may be a food or a medicine.
[0014] The beneficial technical effects of the above one or more technical solutions are as follows:
[0015] The above technical solution obtains Lactobacillus plantarum through screening, and successfully develops a postbiotic preparation product based on this strain. Tests have verified that the postbiotic preparation has the effect of promoting smooth muscle contraction, repairing pelvic floor muscle damage, and relatively quickly repairing stress urinary incontinence. In addition, the condition parameters of the production process of the postbiotic preparation are optimized, and Lactobacillus plantarum is subjected to stepwise fermentation, which realizes the advantages of shortening the fermentation period and comprehensive and abundant metabolic products, which is more suitable for industrialized production, and therefore has good practical value. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] It should be noted that the following detailed description is all illustrative and is intended to further explain the present invention. Unless otherwise specified, all technical and scientific terms used in the present invention have the same meaning as commonly understood by those skilled in the art.
[0017] It should be noted that the terms used herein are not intended to limit the exemplary embodiments according to the present application, but are merely intended to describe specific embodiments. Unless otherwise expressly indicated by the context, the singular forms used herein are intended to include the plural forms, and it should be further understood that when the terms "comprise" and / or "consist of" are used herein, they indicate the presence of features, steps, operations, devices, components, and / or combinations thereof.
[0018] In a specific embodiment of the present invention, there is provided Lactobacillus plantarum Nice-02, which is deposited in the China Typical Culture Preservation Center (Address: Wuhan University, Luojiashan, Wuchang, Wuhan City, Hubei Province), the date of deposit is April 21, 2023, and the biological deposit number is CCTCC NO:M 2023571.
[0019] In a second aspect of the present invention, there is provided a microbial agent, which contains at least the above-mentioned Lactobacillus plantarum and / or a fermentation metabolite thereof.
[0020] Furthermore, the microbial agent includes inactivated Lactobacillus plantarum and its fermentation metabolites, including, but not limited to, extracellular polysaccharides, polypeptides, and amino acids, in which case the microbial agent is a postbiotic preparation.
[0021] Therefore, in a third aspect of the present invention there is provided a method for producing the microbial agent as defined above, said method comprising the steps S1, S2, S3, S4, S5, S6, S7, S8 and S9.
[0022] For the S1 bacterial species activation, the Lactobacillus plantarum Nice-02 was streaked onto the activation medium to obtain a pure strain.
[0023] Here, the composition of the activation medium is 0.05-0.2% casein, 0.05-0.2% sialic acid, 0.3-1.0% beef extract, 0.5-2% peptone, 0.05-0.2% sodium acetate, 0.05-0.2% potassium dihydrogen phosphate, and 1.5-2.0% agar powder, and the pH is adjusted to 7.0.
[0024] More specifically, the composition of the activation medium is 0.1% casein, 0.1% sialic acid, 0.7% beef extract, 1% peptone, 0.1% sodium acetate, 0.1% potassium dihydrogen phosphate, and 2.0% agar powder, and the pH is adjusted to 7.0.
[0025] In preparing the primary seed solution in step S2, a single colony of Lactobacillus plantarum Nice-02 produced in step S1 is picked up and placed in the first culture solution at 28 to 30°C, and cultured statically for 12 to 14 hours to obtain the primary seed solution.
[0026] The composition of the first culture medium is 0.05-0.2% casein, 0.05-0.2% sialic acid, 1-5% fructooligosaccharide, 0.1-1% yeast powder, 0.05-0.2% sodium acetate, and 0.05-0.2% potassium dihydrogen phosphate, and the pH is adjusted to 7.0.
[0027] More specifically, the composition of the first culture medium is 0.1% casein, 0.1% sialic acid, 3% fructooligosaccharide, 0.5% yeast powder, 0.1% sodium acetate, and 0.1% potassium dihydrogen phosphate, and the pH is adjusted to 7.0.
[0028] In preparing the secondary seed solution of S3, the above-mentioned primary seed solution is inoculated into the second culture solution at an inoculation amount of 0.1 to 5% (preferably 0.5%, v / v), and the solution is subjected to static culture at 30 to 40°C (preferably 37°C) for 10 to 12 hours to obtain the secondary seed solution.
[0029] The second culture medium has a composition of 0.1 to 1% casein, 0.05 to 0.2% sialic acid, 1 to 3% fructooligosaccharide, 0.1 to 1% yeast powder, and 0.05 to 0.2% Tween 80, and its pH remains natural.
[0030] More specifically, the second culture medium had a composition of 0.5% casein, 0.1% sialic acid, 1.5% fructooligosaccharide, 0.5% yeast powder, and 0.1% Tween 80, and the pH was kept natural.
[0031] In preparing the tertiary seed solution S4, the secondary seed solution cultured as described above is inoculated into a seed tank containing a third culture solution under sterile conditions, the inoculum amount is 0.5 to 5% (preferably 2%), and the culture is performed by stirring at 20 to 50 rpm (preferably 30 rpm), the temperature is 30 to 40°C (preferably 37°C), the pH is 7.0, the tank pressure is 0.03 to 0.06 MPa (preferably 0.05 MPa), and the culture is performed for 10 to 12 hours to obtain the tertiary seed solution.
[0032] The composition of the third culture medium is 0.5 to 5% peptone, 1 to 5% isomaltooligosaccharide, 0.1 to 0.5% dipotassium hydrogen phosphate, 0.5 to 5% glycine, 0.1 to 1% tyrosine, 0.05 to 0.2% Tween 80, and 0.05 to 0.2% polyether antifoaming agent, and the pH is kept natural.
[0033] Specifically, the composition of the third culture medium was 1% peptone, 4% isomaltooligosaccharide, 0.2% dipotassium hydrogen phosphate, 1% glycine, 0.5% tyrosine, 0.1% Tween 80, and 0.1% polyether antifoaming agent, and the pH value was kept natural.
[0034] In the primary fermentation of S5 Lactobacillus plantarum, the above-mentioned tertiary seed liquid is inoculated into a fermentation tank containing a sterilized culture medium, and the inoculum amount is 0.5-5% (preferably 2%), and the culture is performed at 32°C and 40-50 r / min (preferably 45 r / min) for 5-6 hours.
[0035] The composition of the culture medium was 3% isomaltooligosaccharide, 0.2% casein, 2% peptone, 5% fructooligosaccharide, 3% water-soluble starch, 0.1% Tween 80, 0.5% glycine, 0.5% tyrosine, and 0.2% polyether antifoaming agent, with the pH kept natural.
[0036] In the secondary fermentation of S6 Lactobacillus plantarum, after 5-6 hours, the fermentation temperature is lowered to 30°C, the agitation speed is increased to 50-70 r / min (preferably 60 r / min), the tank pressure is maintained at 0.05 MPa, and the pH is left natural for 3-4 hours of fermentation.
[0037] For the tertiary fermentation of S7 Lactobacillus plantarum, after 8-10 hours, keep the stirring speed unchanged, increase the fermentation temperature to 35°C, maintain the tank pressure at 0.05MPa, and maintain the pH at 6.5 for 2 hours of fermentation.
[0038] In the fourth fermentation of S8 Lactobacillus plantarum, after 10-12 hours, reduce the agitation speed to 30-40 r / min (preferably 40 r / min), increase the fermentation temperature to 40°C, maintain the tank pressure at 0.05 MPa, maintain the pH at 6.5, and ferment for 1-2 hours.
[0039] For the fifth fermentation of S9 Lactobacillus plantarum, after 11-14 hours, without changing the stirring speed, increase the temperature to 45°C, add 0.05-0.2% (preferably 0.1%) of sterile lipoteichoic acid by volume of the fermentation liquid to the fermentation tank, reduce the temperature to 20°C, and maintain for 30 minutes.
[0040] The method further includes a step of subjecting the fermentation liquid produced in step S9 to high-temperature inactivation and spray drying. Specifically, the high-temperature inactivation is performed by holding the fermentation liquid at 75°C for 40 minutes, and then spray drying is performed after lowering the temperature. The spray drying is performed by setting the inlet air temperature at 150 to 180°C and the outlet air temperature at 90 to 100°C, and a postbiotic preparation powder is obtained by spray drying.
[0041] In yet another specific embodiment of the present invention, there is provided the application of said postbiotic formulation in the manufacture of a pelvic floor muscle repair product.
[0042] The pelvic floor muscle repair product may be a food or a medicine.
[0043] More specifically, the pharmaceutical product may contain at least one other inactive pharmaceutical ingredient.
[0044] The inactive pharmaceutical ingredient may be a carrier, excipient, diluent, etc. that is commonly used in pharmacology, and may be made into oral preparations such as powders, granules, suspensions, emulsions, syrups, sprays, etc. according to conventional methods.
[0045] The non-pharmaceutical active ingredients, such as carriers, excipients and diluents that may be included, are well known in the art and may be determined by the skilled artisan to meet clinical standards.
[0046] In yet another specific embodiment of the present invention, the carriers, excipients and diluents include, but are not limited to, lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginates, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc powder, magnesium stearate and mineral oil.
[0047] The present invention will be further described below with reference to examples, but these examples are not intended to be limiting of the present invention. It should be understood that these examples are intended only to illustrate the present invention and do not limit the scope of the present invention. In the examples, the "%" of the composition of each medium (liquid) is a mass volume percentage, and the unit is g / mL.
[0048] Example 1 A method for producing a postbiotic for repairing pelvic floor muscles, comprising the steps of:
[0049] On a sterile operating table, Lactobacillus plantarum Nice-02 stored in a -80 °C low-temperature refrigerator is streaked onto a medium plate, single colonies are screened, and the single colonies are activated three times to obtain a pure strain.
[0050] The composition of the medium is 0.1% casein, 0.1% sialic acid, 0.7% beef extract, 1% peptone, 0.1% sodium acetate, 0.1% potassium dihydrogen phosphate, and 2.0% agar powder per 100 milliliters of medium, and the pH is adjusted to 7.0 with potassium hydroxide.
[0051] A single colony is picked up into 100mL of liquid medium (the medium is placed in a 15*200 test tube, and the liquid medium contains 0.1% casein, 0.1% sialic acid, 3% fructooligosaccharide, 0.5% yeast powder, 0.1% sodium acetate, and 0.1% potassium dihydrogen phosphate per 100 milliliters of medium, and the pH is adjusted to 7.0 with potassium hydroxide), and cultured statically at 30°C for 12 hours.
[0052] The above cultured seed liquid is inoculated into an Erlenmeyer flask medium, with an inoculation amount of 0.5%, that is, 100 mL of secondary seed culture liquid (containing 0.5% casein, 0.1% sialic acid, 1.5% fructooligosaccharide, 0.5% yeast powder, and 0.1% Tween 80 per 100 mL of culture liquid, with a natural pH) is inoculated with 0.5 mL of primary seed liquid. After inoculation, the bottle is sealed with sterile gauze and craft paper, and shaken slightly by hand to mix the inoculated bacterial species evenly with the culture liquid. Then, it is placed in a thermostatic box and cultured at 37°C for 12 hours, which is called the secondary seed liquid.
[0053] The secondary seed liquid cultured above is inoculated under aseptic conditions into a seed tank containing a tertiary seed culture medium (containing 1% peptone, 4% isomaltooligosaccharide, 0.2% dipotassium hydrogen phosphate, 1% glycine, 0.5% tyrosine, 0.1% Tween 80, and 0.1% polyether antifoaming agent per 100 milliliters of medium, with the pH kept natural), with an inoculum amount of 2% (v / v), and cultured at 30 rotations / min under stirring at a temperature of 37°C, pH of 7.0, and tank pressure of 0.05 MPa for 12 hours.
[0054] The tertiary seed liquid is inoculated into a fermentation tank containing a sterile fermentation liquid (containing 3% isomalto-oligosaccharide, 0.2% casein, 2% peptone, 5% fructooligosaccharide, 3% water-soluble starch, 0.1% Tween 80, 0.5% glycine, 0.5% tyrosine, and 0.2% polyether antifoaming agent per 100 milliliters of medium, and the pH value is natural), with an inoculum amount of 2% (v / v), and cultured at 32°C and 45r / min for 5 hours. After 5 hours, the fermentation temperature is lowered to 30°C, the agitation rotation speed is increased to 60r / min, the tank pressure is maintained at 0.05MPa, and the pH value is fermented for 3 hours with the pH value remaining natural. After 8 hours, the agitation speed is not changed, the fermentation temperature is increased to 35°C, the tank pressure is maintained at 0.05MPa, and the pH value is maintained at 6.5 by the acid-alkali automatic adjustment control system, and the fermentation is carried out for 2 hours. After 10 hours, reduce the stirring speed to 40r / min, increase the fermentation temperature to 40℃, maintain the tank pressure at 0.05MPa, maintain pH 6.5 by the acid-alkali automatic adjustment control system, and ferment for 1 hour. After 11 hours, without changing the stirring speed, increase the temperature to 45℃, add 0.1% of sterilized lipoteichoic acid by volume of the fermentation liquid to the fermentation tank, reduce the temperature to 20℃ and maintain for 30 minutes, then increase to 75℃ and maintain for 40 minutes to inactivate, then reduce to 30℃.
[0055] The inlet air temperature is set to 150-180°C and the outlet air temperature to 90-100°C, and spray drying is carried out to obtain the postbiotic powder.
[0056] The postbiotic obtained in Example 1 has an extracellular polysaccharide content of 24%, a polypeptide content of 20.8% and an amino acid content of 38.5%.
[0057] Example 2 A method for producing a postbiotic for repairing pelvic floor muscles, comprising the steps of:
[0058] On a sterile operating table, Lactobacillus plantarum Nice-02 stored in a -80 °C low-temperature refrigerator is streaked onto a medium plate, single colonies are screened, and the single colonies are activated three times to obtain a pure strain.
[0059] The composition of the medium is 0.1% casein, 0.1% sialic acid, 0.7% beef extract, 1% peptone, 0.1% sodium acetate, 0.1% potassium dihydrogen phosphate, and 2.0% agar powder per 100 milliliters of medium, and the pH is adjusted to 7.0 with potassium hydroxide.
[0060] A single colony is picked up into 100mL of liquid medium (the medium is placed in a 15*200 test tube, and the liquid medium contains 0.1% casein, 0.1% sialic acid, 3% fructooligosaccharide, 0.5% yeast powder, 0.1% sodium acetate, and 0.1% potassium dihydrogen phosphate per 100 milliliters of medium, and the pH is adjusted to 7.0 with potassium hydroxide), and cultured statically at 30°C for 12 hours.
[0061] The above cultured seed liquid is inoculated into an Erlenmeyer flask medium, with an inoculation amount of 0.5%, that is, 100 mL of secondary seed culture liquid (containing 0.5% casein, 0.1% sialic acid, 1.5% fructooligosaccharide, 0.5% yeast powder, and 0.1% Tween 80 per 100 mL of culture liquid, with a natural pH) is inoculated with 0.5 mL of primary seed liquid. After inoculation, the bottle is sealed with sterile gauze and craft paper, and shaken slightly by hand to mix the inoculated bacterial species evenly with the culture liquid. Then, it is placed in a thermostatic box and cultured at 37°C for 12 hours, which is called the secondary seed liquid.
[0062] The secondary seed liquid cultured above is inoculated under aseptic conditions into a seed tank containing a tertiary seed culture liquid (containing 1% peptone, 4% isomaltooligosaccharide, 0.2% dipotassium hydrogen phosphate, 1% glycine, 0.5% tyrosine, 0.1% Tween 80, and 0.1% polyether antifoaming agent per 100 milliliters of medium, with the pH remaining natural), with an inoculum amount of 2%, and cultured at 30 rotations per minute under stirring at a temperature of 37°C, pH of 7.0, and tank pressure of 0.05 MPa for 12 hours.
[0063] The tertiary seed liquid is inoculated into a fermentation tank containing a sterile fermentation liquid (containing 3% isomalto-oligosaccharide, 0.2% casein, 2% peptone, 5% fructooligosaccharide, 3% water-soluble starch, 0.1% Tween 80, 0.5% glycine, 0.5% tyrosine, and 0.2% polyether antifoaming agent per 100 milliliters of medium, and the pH value is natural), with an inoculum amount of 2%, and cultured at 32°C and 45r / min for 46 hours. After 46 hours, the stirring speed is not changed, the temperature is raised to 45°C, and 0.1% of the volume of the fermentation liquid of sterile lipoteichoic acid is added to the fermentation tank, the temperature is lowered to 20°C, maintained for 30 minutes, then raised to 75°C and maintained for 40 minutes to inactivate, and then lowered to 30°C.
[0064] The inlet air temperature is set to 150-180°C and the outlet air temperature to 90-100°C, and spray drying is carried out to obtain the postbiotic powder.
[0065] The postbiotic obtained in Example 2 has an extracellular polysaccharide content of 19%, a polypeptide content of 17.8% and an amino acid content of 34%.
[0066] Effect verification 1. In vitro muscle contraction evaluation The duodenal smooth muscle was used as the experimental subject, and the effect of the postbiotic product on the contraction performance of the duodenal smooth muscle was observed and measured. The experimental method was as follows: the rats were divided into a control group and an experimental group; the control group was fed normally, and the experimental groups were fed with 0.5% (w / w), 1.0% and 1.5% postbiotics (all of which were the products produced in Example 1, and the three experimental groups were named experimental groups 1 to 3, respectively). After feeding for about two weeks, the rats were anesthetized and killed by neck dislocation. The rats' abdomen was incised, and the intestines were cut from the boundary between the stomach pylorus and the duodenum as the starting point, cut into intestinal sections of about 1 cm, lightly washed with Krebs solution, and left in Krebs solution, moisturized, and kept at a constant temperature of 37°C. The basal tension was adjusted to 1 g, and the mixed gas (950 mL·L) was blown into the ventilated hook at a rate of 1 to 2 bubbles per second. -1 of oxygen and 50 mL L -1 The small intestinal smooth muscle contractile activity and change signals were transferred to the BL-420 biological function experiment multi-channel physiological signal acquisition and processing system by a tension transducer, and the contraction curve was observed. The results are shown in Table 1. From the results in Table 1, postbiotics have the ability to promote smooth muscle contraction and show a certain dose-dependency.
[0067] [Table 1]
[0068] 2. Small-scale clinical trials of pelvic floor muscle injury treatment Twenty women aged 40-60 years old voluntarily participated in the study and were able to complete the questionnaire and records. Those who suffered from stress urinary incontinence due to pelvic floor muscle problems were included in the study group. Every morning, 600 mg of postbiotics (the product manufactured in Example 1) was orally taken on an empty stomach for three weeks. During this period, the urinary incontinence situation was tested by jumping rope every week. During the intake period, the original eating habits were not changed and the subjects ate normally.
[0069] After the end of the treatment cycle, 100% of participants stated that their previous exercise method involved barely any jumping and only a few jumps would result in urinary leakage, whereas after they stopped taking the drug, they had no urinary leakage or even felt any leakage at all throughout the entire skipping rope process.
[0070] [Table 2]
[0071] The above-mentioned efficacy verification experiment revealed that the postbiotic preparation produced according to the present invention has a relatively strong pelvic floor muscle repair function.
[0072] Finally, it should be noted that the above are only preferred embodiments of the present invention, and are not intended to limit the present invention. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art may still modify the technical solutions described in the above embodiments or replace part of them with equivalents. All modifications, equivalent replacements, improvements, etc. made without departing from the spirit and principles of the present invention shall be included within the protection scope of the present invention. Although the above is a description of a specific embodiment of the present invention, it is not a limitation on the protection scope of the present invention, and those skilled in the art should understand that various modifications or variations obtained by those skilled in the art based on the technical solutions of the present invention without creative efforts are still within the protection scope of the present invention.
Claims
1. Lactobacillus plantarum Nice-02, deposited at the China Typical Culture Preservation Center, with the date of deposit on April 21, 2023, and the biological accession number CCTCC NO: M 2023571.
2. A microbial agent comprising at least the Lactobacillus plantarum Nice-02 according to claim 1.
3. The microbial agent according to claim 2, characterized in that it comprises inactivated Lactobacillus plantarum Nice-02.
4. S1 A step of strain activation in which the Lactobacillus plantarum Nice-02 is streaked on an activation medium to obtain a pure strain; S2: A step of preparing a primary seed solution by picking up the Lactobacillus plantarum Nice-02 single colony produced in step S1, placing it in a first culture solution at 28 to 30 ° C., and statically culturing it for 12 to 14 hours to obtain a primary seed solution; S3: A step of preparing a secondary seed liquid by inoculating the above-mentioned primary seed liquid into a second culture liquid at an inoculation amount of 0.1 to 5% and statically culturing the liquid at 30 to 40° C. for 10 to 12 hours to obtain a secondary seed liquid; S4: A step of preparing a third seed liquid by inoculating the second seed liquid cultured above into a seed tank containing a third culture liquid under sterile conditions, with an inoculation amount of 0.5-5%, agitation culture at 20-50 rpm, a temperature of 30-40° C., a pH of 7.0, a tank pressure of 0.03-0.06 MPa, and culture for 10-12 hours to obtain a third seed liquid; S5: The tertiary seed liquid is inoculated into a fermentation tank containing a sterilized culture medium, and the inoculation amount is 0.5-5%, and the Lactobacillus plantarum is cultured at 32°C and 40-50 r / min for 5-6 hours for primary fermentation; S6 After 5-6 hours, the fermentation temperature is lowered to 30°C, the stirring speed is increased to 50-70r / min, the tank pressure is maintained at 0.05MPa, and the pH is kept natural for 3-4 hours for the secondary fermentation of Lactobacillus plantarum; S7 After 8-10 hours, the stirring speed is not changed, the fermentation temperature is increased to 35 ° C, the tank pressure is maintained at 0.05 MPa, the pH is maintained at 6.5, and fermentation is continued for 2 hours. S8 After 10 to 12 hours, the stirring speed is reduced to 30 to 40 r / min, the fermentation temperature is increased to 40 ° C, the tank pressure is maintained at 0.05 MPa, the pH is maintained at 6.5, and the Lactobacillus plantarum quaternary fermentation step is performed for 1 to 2 hours; S9. After 11-14 hours, the stirring speed is not changed, the temperature is increased to 45°C, 0.05-0.2% of the volume of the fermented liquid is added to the fermentation tank with sterilized lipoteichoic acid, and the temperature is decreased to 20°C and maintained for 30 minutes, which is the fifth fermentation step of Lactobacillus plantarum.
5. In step S1, The method according to claim 4, characterized in that the activation medium has a composition of 0.05-0.2% casein, 0.05-0.2% sialic acid, 0.3-1.0% beef extract, 0.5-2% peptone, 0.05-0.2% sodium acetate, 0.05-0.2% potassium dihydrogen phosphate, and 1.5-2.0% agar powder, and has a pH adjusted to 7.
0.
6. The method according to claim 5, characterized in that the activation medium has a composition of 0.1% casein, 0.1% sialic acid, 0.7% beef extract, 1% peptone, 0.1% sodium acetate, 0.1% potassium dihydrogen phosphate, and 2.0% agar powder, and is adjusted to a pH of 7.
0.
7. In step S2, The method according to claim 4, characterized in that the first culture solution has a composition of 0.05 to 0.2% casein, 0.05 to 0.2% sialic acid, 1 to 5% fructooligosaccharide, 0.1 to 1% yeast powder, 0.05 to 0.2% sodium acetate, and 0.05 to 0.2% potassium dihydrogen phosphate, and has a pH adjusted to 7.
0.
8. The method for producing a yeast culture medium according to claim 7, characterized in that the composition of the first culture medium is 0.1% casein, 0.1% sialic acid, 3% fructooligosaccharide, 0.5% yeast powder, 0.1% sodium acetate, and 0.1% potassium dihydrogen phosphate, and the pH is adjusted to 7.
0.
9. In step S3, The method according to claim 4, wherein the second culture solution has a composition of 0.1-1% casein, 0.05-0.2% sialic acid, 1-3% fructooligosaccharide, 0.1-1% yeast powder, and 0.05-0.2% Tween 80, and the pH is kept natural.
10. The method according to claim 9, wherein the second culture solution has a composition of 0.5% casein, 0.1% sialic acid, 1.5% fructooligosaccharide, 0.5% yeast powder, and 0.1% Tween 80, and the pH is kept natural.
11. The method according to claim 4, wherein in step S4, the third culture solution has a composition of 0.5 to 5% peptone, 1 to 5% isomaltooligosaccharide, 0.1 to 0.5% dipotassium hydrogen phosphate, 0.5 to 5% glycine, 0.1 to 1% tyrosine, 0.05 to 0.2% Tween 80, and 0.05 to 0.2% polyether antifoaming agent, and the pH is kept natural.
12. The method according to claim 11, characterized in that the third culture solution has a composition of 1% peptone, 4% isomaltooligosaccharide, 0.2% dipotassium hydrogen phosphate, 1% glycine, 0.5% tyrosine, 0.1% Tween 80, and 0.1% polyether antifoaming agent, and has a natural pH value.
13. The method according to claim 4, characterized in that the composition of the culture medium used in the multi-stage fermentation process is 3% isomalto-oligosaccharides, 0.2% casein, 2% peptone, 5% fructooligosaccharides, 3% water-soluble starch, 0.1% Tween 80, 0.5% glycine, 0.5% tyrosine, 0.2% polyether antifoaming agent, and the pH is natural.
14. The method according to any one of claims 4 to 13, further comprising the step of subjecting the fermentation liquid produced in step S9 to high-temperature inactivation and spray drying.
15. Use of the Lactobacillus plantarum Nice-02 according to claim 1 or the microbial agent according to claim 2 or 3 in the manufacture of a pelvic floor muscle repair product.
Citation Information
Patent Citations
Postbiotic preparation for repairing pelvic floor muscle as well as preparation method and application thereof
CN116536201A
Isolated microbial strains, Lactobacillus plantarum MCC1DSM23881 and Lactobacillus gasseri MCC2DSM23882, and their uses.
JP2014506475A
Active substance of lactobacillus plantarum gkm3, composition comprising thereof and its use for promoting longevity
JP2020059694A
Composition for alleviating symptoms of overactive bladder
JP2020176094A
Composite probiotic composition for alleviating overactive bladder-related symptom
JP2023072623A
